202 related articles for article (PubMed ID: 25918240)
1. Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.
Ferguson DC; Cheng Q; Blanco JG
Drug Metab Dispos; 2015 Jul; 43(7):922-7. PubMed ID: 25918240
[TBL] [Abstract][Full Text] [Related]
2. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
[TBL] [Abstract][Full Text] [Related]
3. A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.
Gonzalez-Covarrubias V; Ghosh D; Lakhman SS; Pendyala L; Blanco JG
Drug Metab Dispos; 2007 Jun; 35(6):973-80. PubMed ID: 17344335
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional regulation of the canine carbonyl reductase 1 gene (cbr1) by the specificity protein 1 (Sp1).
Quiñones-Lombraña A; Cheng Q; Ferguson DC; Blanco JG
Gene; 2016 Oct; 592(1):209-214. PubMed ID: 27506315
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).
Gonzalez-Covarrubias V; Kalabus JL; Blanco JG
Pharm Res; 2008 Jul; 25(7):1730-4. PubMed ID: 18449627
[TBL] [Abstract][Full Text] [Related]
6. Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.
Quiñones-Lombraña A; Ferguson D; Hageman Blair R; Kalabus JL; Redzematovic A; Blanco JG
Pharm Res; 2014 Jul; 31(7):1644-55. PubMed ID: 24562808
[TBL] [Abstract][Full Text] [Related]
7. Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase--Carbonyl reductase 1.
Hintzpeter J; Hornung J; Ebert B; Martin HJ; Maser E
Chem Biol Interact; 2015 Jun; 234():162-8. PubMed ID: 25541467
[TBL] [Abstract][Full Text] [Related]
8. Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro.
Takahashi RH; Bains OS; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2008 Jun; 36(6):991-4. PubMed ID: 18322072
[TBL] [Abstract][Full Text] [Related]
9. Expression of the anthracycline-metabolizing enzyme carbonyl reductase 1 in hearts from donors with Down syndrome.
Kalabus JL; Sanborn CC; Jamil RG; Cheng Q; Blanco JG
Drug Metab Dispos; 2010 Dec; 38(12):2096-9. PubMed ID: 20729274
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibition of human carbonyl reductase 1 (CBR1) by the prenylated chalconoid xanthohumol and its related prenylflavonoids isoxanthohumol and 8-prenylnaringenin.
Seliger JM; Martin HJ; Maser E; Hintzpeter J
Chem Biol Interact; 2019 May; 305():156-162. PubMed ID: 30849340
[TBL] [Abstract][Full Text] [Related]
11. Flavonoids as inhibitors of human carbonyl reductase 1.
Carlquist M; Frejd T; Gorwa-Grauslund MF
Chem Biol Interact; 2008 Jul; 174(2):98-108. PubMed ID: 18579125
[TBL] [Abstract][Full Text] [Related]
12. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
Blanco JG; Sun CL; Landier W; Chen L; Esparza-Duran D; Leisenring W; Mays A; Friedman DL; Ginsberg JP; Hudson MM; Neglia JP; Oeffinger KC; Ritchey AK; Villaluna D; Relling MV; Bhatia S
J Clin Oncol; 2012 May; 30(13):1415-21. PubMed ID: 22124095
[TBL] [Abstract][Full Text] [Related]
14. DNA sequence variants in the carbonyl reductase 1 (cbr1) gene in seven breeds of Canis lupus familiaris.
Cheng Q; Sanborn C; Ferguson D; Blanco JG
Genet Mol Res; 2012 Apr; 11(2):1109-16. PubMed ID: 22614280
[TBL] [Abstract][Full Text] [Related]
15. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes.
Plebuch M; Soldan M; Hungerer C; Koch L; Maser E
Cancer Lett; 2007 Sep; 255(1):49-56. PubMed ID: 17482758
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
17. S-nitrosoglutathione covalently modifies cysteine residues of human carbonyl reductase 1 and affects its activity.
Hartmanová T; Tambor V; Lenčo J; Staab-Weijnitz CA; Maser E; Wsól V
Chem Biol Interact; 2013 Feb; 202(1-3):136-45. PubMed ID: 23295225
[TBL] [Abstract][Full Text] [Related]
18. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics.
Jamrozik M; Piska K; Bucki A; Koczurkiewicz-Adamczyk P; Sapa M; Władyka B; Pękala E; Kołaczkowski M
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175180
[TBL] [Abstract][Full Text] [Related]
19. Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin.
Bains OS; Takahashi RH; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2008 May; 36(5):904-10. PubMed ID: 18276838
[TBL] [Abstract][Full Text] [Related]
20. Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods.
Pirolli D; Giardina B; Mordente A; Ficarra S; De Rosa MC
Eur J Med Chem; 2012 Oct; 56():145-54. PubMed ID: 22982121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]